Upotreba suplemenata u tretmanu pacijenata sa bipolarnim poremećajem
Sažetak
Poslednjih godina postoji sve veće interesovanje naučne javnosti za korišćenje suplemenata kao adjuvantne terapije u lečenju različitih psihijatrijskih poremećaja. Suplementi se posmatraju kao dopuna tradicialnim farmakoterpijskim i psihoterapijskim principima pružajući personalizovaniji pristup lečenju. Veliki je broj istraživanja koja su se bavila njihovim mogućim uticajem na različite biološke procese kao što su neurogeneza, neoroprogresija, oksidativni stres, inflamacija, mitohondrijalna disfunkcija i drugi. Iako su dokazi o efikasnosti suplemenata u lečenju psihijatrijskih poremećaja još uvek u razvoju, postoji sve više naučnih istraživanja koja podržavaju njihove potencijalne benefite. Integrativni, savremeni terapijski pristup bipolarnom poremećaju sve više uključuje upotrebu suplemenata kao adjuvantnu terapiju obzirom na složenost kliničke slike poremećaja. U ovom radu biće prikazana dosadašnja istraživanja o upotrebi suplemenata u bipolarnom poremećaju, kao i potencijalni benefiti. Dokazi (ili nedostatak istih) o najznačajnijim i najviše ispitivanim suplementima će takođe biti navedeni, kao i perspektiva i mesto suplemenata u terapiji bipolarnog poremećaja.
Reference
1. Ivković M, Pantović Stefanović M, Nešić M, Dodić S, Dunjić-Kostić B. Poremećaji raspoloženja. In: Latas M, Ivković M, Janjić V, editors. Psihopatologija u okvirima MKB-11. CEDUP; 2022. p.91-127.
2. World Health Organization, International Classification of Diseases, Eleventh Revision (ICD-11), 2019/2021
3. Pantović Stefanović M, Dunjić-Kostić B, Velimirović M, Nikolić T, Lačković M, Damjanović A, Petronijević N, Ivković M. Shizoafektivni kontinuum-stari koncept u novom svetlu. 44th Educational Symposiaof the Clinic for Psychiatry Clinical Center of Serbia, Beograd, Srbija, Engrami 2017; 39(1): S14,p30
4. Drancourt N, Etain B, Lajnef M, Henry C, Raust A, et al. (2013) Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand 127: 136–144. doi: 10.1111/j.1600-0447.2012.01917.x PMID: 22901015
5. Boland R, Verduin M, Ruiz P, editors. Kaplan & Sadock’s Synopsis of Psychiatry 12ed. Philadephia (USA): Walter Clowers; 2021.
6. Ivković M, Pantović Stefanović M. Farmakološki tretman bipolarnog afektivnog poremećaja. In: Latas M, Ivković M, Janjić V, editors. Farmakoterapija u psihijatriji, Farmakoterapija u psihijatriji, Beograd: CEDUP; 2019. p. 133-48.
7.Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. Drug Dev Res. 2016; 77(7):357-367.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5. Arlington: American Psychiatric Publishing; 2013.
9. Ivkovic M, Pantovic Stefanovic M, Dunjic-Kostic B, Jurisic V, Lackovic M, Totic- Poznanovic S, Jovanovic AA, Damjanovic A. Predictive value of sICAM-1 and sVCAM-1 as biomarkers of affective temperaments in healthy young adults. J Affect Disord 2017; 207:47-52.
10. Pantović-Stefanović M, Petronijević N, Dunjić-Kostić B, Velimirović M, Nikolić T, Jurišić V, Lačković M, Damjanović A, Totić-Poznanović S, Jovanović AA, Ivković M. sVCAM-1, sICAM-1, TNF-α and IL-6 levels in bipolar disorder type I: Acute, longitudinal and therapeutic implications. World J Biol Psychiatry 2016; 14:1-11.
11. Vidovic B, Milovanovic S, Djordjevic B, Kotur-Stevuljevic J, Stefanovic A, Miljkovic M,Spasic S, Stojanovic D, Pantovic M. Effect of alpha-lipoic acid on oxidatuve stress markersand oxidative defense in patients with schizophrenia. Psychiatria Danubina 2014; 26(3):205-2013.
12. Pantovic Stefanovic M, Dunjic-Kostic B, Lackovic M, Damjanovic A,Jovanovic A, Totic-Poznanovic S, Ivkovic M. C-reactive protein levels are related to suicidality in euthymic patients with bipolar disorder. 24th European Congress of Psychiatry, Madrid, Spain; European Psychiatry 2016; 33S : S290–S643
13. Food and Drug Administration. Questions and Answers on Dietery Supplements [Internet].[Place unknown]: FDA;2002 [updated 2022 Oct 26 cited 2022 Nov 16] Available from:https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
14. Fusar-Poli L, Surace T, Vanella A, Meo V, Patania F, Furnari R, et al. The effect of adjunctive nutraceuticals in bipolar disorder: A systematic review of randomized placebo-controlled trials. J Affect Disord 2019; 252: 334-349
15. Sylvia LG, Peters AT, Deckerbasch T, Nierenberg AA. Nutrient-based therapies for bipolar disorder: A systematic review. Psychother Psychosom 2013; 82:10-19.
16. Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord 2014; 169 Suppl 1: S34-44.
17. Fung VC, Overhage LN, Sylvia LG, Reilly-Harrington NA, Kamali M, Gao Ket al. Complex polypharmacy in bipolar disorder: side effect burden, adherence, and response predictors. J Affect Disord. 2019: 257: 17–22.
18.OlagunjuAT, Morgan JA, Aftab A, Gatchel JR, Chen P, Dols A, et al. A review of the evidence base for nutrition and nutritional supplements in older adults with bipolar disorder: A report from the OABD task force. J Frailty Aging 2021; 10(3): 241–246.
19. Ashton MM, Berk M, Ng CH, Hopwood M, Kavanagh B, Williams LJ, et al. Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for systematic review. BMJ Open 2019; 9:e025640. [5p.]
20. Beyer JL, Payne ME. Nutrition and bipolar depression. Psychiatr Clin N Am 2016; 39: 75-86.
21. Adzic M, Brkic Z, Mitic M, Francija E, Jovicic MJ, Radulovic J, Maric NP. Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr Neuropharmacol. 2018; 16(2):176-209. inflamacija u depresiji
22. Jovicic M, Maric NP, Soldatovic I, Lukic I, Andric S, Mihaljevic M, Pavlovic Z, Mitic M, Adzic M. The role of glucocorticoid receptor phosphorylation in the model of negative affective states. World J Biol Psychiatry. 2015;16(5):301-11
23. Jovicic MJ, Lukic I, Radojcic M, Adzic M, Maric NP. Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. Med Hypotheses. 2015;85(3):291-4.
24. Lukic I, Mitic M, Soldatovic I, Jovicic M, Maric N, Radulovic J, Adzic M. Accumulation of cytoplasmic glucocorticoid receptor is related to elevation of FKBP5 in lymphocytes of depressed patients. J Mol Neurosci. 2015;55(4):951-8.
25. Pavlović MD. Ortomolekularna neurologija i psihijatrija. Beograd: Orionart; 2019.
26. Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fitó M, Escoda R, Serrano-Martínez M, Salas-Salvadó J, Benages N, Casas R, Lamuela-Raventós RM, Masanes F, Ros E, Estruch R. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. Am J Clin Nutr. 2009;89(1):248-56.
27. Hoepner CT, McIntyre RS, Papakostas GI. Impact of supplemetation and nutritional interventions on pathogenic processes of mood disorders: A review of the evidence. Nutrients 2021; 13:767. [26p.]
28. Frangou S, Lewis M, McCrone P. Efficacy of ethyleicosapentaenoicacid in bipolar depression: randomiseddouble-blind placebo-controlled study. Br JPsychiatry2006;188:46-50.
29. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Fryeet MA, et al. Double-blind, randomized,placebo-controlled trials of ethyl-eicosapentanoate inthe treatment of bipolar depression and rapid cycling bipolardisorder. Biol Psychiatry 2006;60(9):1020-22
30. Chiu CC, Huang SY, Chen CC, Su KP. Omega-3 fatty acids aremore beneficial in the depressive phase than in the manic phasein patients with bipolar I disorder. J Clin Psychiatry 2005;66(12):1613-4.
31. Ashton MM, Kavanagh BE, Marx W, Berk M, Sarris J, Ng CH, et al. A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. Can J Psychiatry 2020; 66 (3): 262 – 73.
32. Kishi T, Sakuma K, Okuya M, Ikeda M, Iwata N. Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. Bipolar disord 2021; 23:730-1.
33. Cereda G, Enrico P, Ciappolino V, DelvecchioG, Brambilla P. The role of vitamin D in bipolar disorder: epidemiology and influence on disease activity. J Affect Disord 2021; 278:209-17.
34. Pavlović MD. Vitamin B12, Vitamin D i homocistein. Beograd: Orionart; 2018.
35. Sikoglu EM, Navarro AA, Starr D, Dvir Y, Nwosu BU, Czernia SM, et al. Vitamin D3 supplemental treatment for mania in youth with bipolar spectrum disorders. J. Child Adolesc. Psychopharmacol. 2015; 25:415–24.
36. Marsh WK, Penny JL, Rothschild AJ. Vitamin D supplementation in bipolar depression: a double blind placebo controlledtrial. J Psychiatr Res. 2017; 95:48-53.
37. Smaga I, Frankowska M, Filip M. N-acetylcysteine as a new prominent approach for treating psychiatric disorders. Br J Pharmacol 2021; 178: 2569– 94
38. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F,Fernandes BS, et al.The efficacy of N-acetylcysteine as an adjunctive treatment in bipolardepression: An open labeltrial. J Aff Disord 2011; 135(1–3):389–94.
39. EllegaardPK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, et al. The efficacy ofadjunctive N-acetylcysteine in acute bipolar depression: A randomizedplacebo-controlled study. J Aff Disord 2019; 245:1043–51.
40. BerkM, Turner A, Malhi GS., Ng CH., Cotton SM, Dodd S, et al. A randomisedcontrolled trial of a mitochondrial therapeutic target for bipolardepression: Mitochondrialagents, N-acetylcysteine, and placebo. BMCMed 2019; 17(1):18. [11p.]
41. Andrade C. N-Acetylcysteine Augmentation for Patients With Major Depressive Disorder and Bipolar Depression. J Clin Psychiatry 2021; 82(1):21f13891[3p.]
42. Menegas S, Dal-Pont GC, Cararo JH, Varela, Aguiar-Geraldo JM, Possamai-Della T, et al. Efficacy of folic acid as an adjunct to lithium therapy on manic-like behaviors, oxidative stress and inlammatory parameters in an animal model of mania. Metab Brain Dis 2019; 35:413-25.
43. Lam NS, Long XX, Li X, Saad M, Lim F, Doery JC, et al. Potential use of folate and its derivatives in trating psychiatric disorders: A systematic review. Biomed Pharmacother 2021; 146:112541. [18p.]
44. Fryar-Williams S. Fundamental Role of Methylenetetrahydrofolate Reductase 677 C → T Genotype and Flavin Compounds in Biochemical Phenotypes for Schizophrenia and Schizoaffective Psychosis. Front Psychiatry. 2016; 7:172
45. Herbert V, Zalusky R. Inter-relation of vitamin B1 2 and folic acid metabolism: folic acid clearance studies. J Clin Invest 1962; 41: 1263-76.
46. Khosravi M, Sotoudeh G, Amini M, Raisi F, Mansoori A, Hosseinzadeh M. The relationship between dietary patterns and depression mediated by serum levels of Folate and vitamin B12. BMC Psychiatry. 2020; 20(1):63.
47. Hsieh YC, Chou LS, Lin CH, Wu HC, Li DJ, Tseng PT. Serum folate level in bipolar disorder: a systematic review and meta-analysis. BMC Psychiatry 2019; 19:305. [9p.]
48. ZhengW,Li W, Qi H, Xiao L, Sim K, Ungvari GS, et al. Adjunctive folate for major mental disorders: A systematic review. J Affect Disord 2020; 267:123-30.
49. Robinson S, Miller J. J, L-Methylfolate: Augmenting Agent May Contribute to Agitation and Mania. Psichiatric Times 2020; 34(3): 13-14
50. Moretti M, Fraga DB, Rodrigues AL. Ascorbic acid to manage psychiatric disorders. CNS Drugs 2017; 31: 571-83.
51. Williams NT, Probiotics. Am J Health Syst Pharm 2010; 67:449-58.
52. Manoharan N, Jayamurali D, Parasuraman R, Govindarajulu SN. Brain Related Gut Peptides - A Review. Protein Pept Lett. 2022;29(12):1016-1030.
53. Carlessi AS, Borba LA, Zugno AI, Quevedo J, Réus GZ. Gut microbiota-brain axis in depression: The role of neuroinflammation. Eur J Neurosci. 2021;53(1):222-235.
54. Mangiola F, Ianiro G, Franceschi F, Fagiuoli S, Gasbarrini G, Gasbarrini A. Gut microbiota in autism and mood disorders. World J Gastroenterol 2016; 22: 361-68.
55. Halversona T, Alagiakrishnan K. Gut microbes in neurocognitive and mental health disorders. Ann Med. 2020; 52: 423-43.
56. Reininghaus EZ, Wetzlmair LC, Fellendorf FT, Platzer M, Queissner R, Birner A,et al.The impact ofprobiotic supplements on cognitive parameters in euthymicindividuals with bipolar disorder: a pilot study. Neuropsychobiology. 2018; doi:10.1159/000492537[Epub ahead of print]
57. Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savageet C, et al.Adjunctive probioticmicroorganisms to prevent rehospitalization in patients with acutemania: a randomized controlled trial. Bipolar Disord 2018; 20:614–21.
58. Dinan TG, Cryan JF. Gut microbiota: a missing link in psychiatry. World Psychiatry 2020; 19:111-12.
59. (Rude RK, Shils ME. Magnesium. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern nutrition in health and disease, 10th ed. Baltimore: Lippincott Williams & Wilkins, 2006, 223-247.
60. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375–389.
61. Murck H. Ketamine, magnesium and major depression – from pharmacology to pathophysiology and back. J Psychiatr Res. 2013; 47: 955-65.
62. Danysz W, Zajaczkowski W, Parsons CG: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol, 1995, 6, 455–474. // Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A: Magnesium gates glutamate-activated channels in mouse central neurones. Nature, 1984, 307, 462–465.
63. Cardoso CC, Lobato KR, Binfare RW, Ferreira PK, Rosa AO, Santos AR, Rodrigues AL: Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33, 235–242.
64. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375–389.
65. Ordak M., Muszynska E., Nasierowski T., Maj-Zurawska M., Bujalska-Zadrozny M. Level of magnesium in psychiatry - What is the cause of ambiguous results? Gen. Hosp. Psychiatry. 2018; 51:136.
66. Cheungpasitporn W, Thongprayoon C, Mao MA, Srivali N, Ungprasert P, Varothai N. et al. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. Intern. Med. J. 2015; 45(4): 436–440.
67. Ryszewska-Pokra´sniewicz, B.; Mach, A.; Skalski, M.; Januszko, P.; Wawrzyniak, Z.M.; Poleszak, E.; Nowak, G.; Pilc, A.; Radziwo ´n-Zaleska, M. Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response. Nutrients 2018, 10, 1014.
68. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M: Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res 2000; 93: 83–87.
69. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14:171–180.
70. Nielsen, J: Magnesium-lithium studies 1. Serum and erythrocyte magnesium in patients with manic-states during lithium treatment. Acta psychiat. scand.1964; 40, 1 90-1 96
71. Berk, M.; Kapczinski, F.; Andreazza, A.C.; Dean, O.M.; Giorlando, F.; Maes, M.; Yücel, M.; Gama, C.S.; Dodd, S.; Dean, B.; et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35, 804–817
72. Correll, C.U.; Ng-Mak, D.S.; Stafkey-Mailey, D.; Farrelly, E.; Rajagopalan, K.; Loebel, A. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: A real-world analysis. Ann. Gen. Psychiatry 2017, 16, 9
73. Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry 2022; 23(6): 424-55
74. Pfaffenseller, B.; Fries, G.R.; Wollenhaupt-Aguiar, B.; Colpo, G.D.; Stertz, L.; Panizzutti, B.; Magalhães, P.V.; Kapczinski, F. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev. Neurother. 2013, 13, 827–842.
75. Gabriel FC, Oliveira M, Martella BM, Berk M, Brietzke E, Jacka FN, et al. Nutrition and bipolar disorder: a systematic review. Nutr Neurosci 2022.